UTHR: Short Covering Holds, Options Lean Bullish Before Wednesday's Print

United Therapeutics enters its November 4 earnings report with short sellers still exiting, options tilted toward calls, and a stock up 24% over the past month.

The short-covering story that drove last week's 6.7% rally has not reversed. Short interest remains at 5.76% of the free float, roughly 2.5 million shares, after a 31.8% collapse in the week ended October 23. That was one of the most aggressive single-week covering moves in the stock's recent history. Since then, positions have held roughly flat: shares short have barely moved in the four sessions through October 29. The covering was a positioning decision, not a forced exit. Availability remains at 2,740%, meaning lendable shares vastly outnumber those borrowed, and the cost to borrow is just 0.48%. There is no mechanical squeeze pressure in the lending market.

Options positioning reinforces the cautious-bullish tilt. The put/call ratio is 0.60, roughly 0.7 standard deviations below its 20-day average of 0.69, reflecting continued call-side dominance. That said, this is far from an extreme reading. The PCR sat above 0.90 throughout late September and most of October before collapsing in mid-October alongside the short covering, and it has drifted slightly higher again in the past week. Call buyers remain in control, but conviction is not emphatic.

The analyst community is broadly positive but applying some restraint into the print. JP Morgan trimmed its target from $710 to $695 on October 28 while holding an Overweight rating. RBC Capital made a similar trim to $697, also maintaining Outperform. Leerink Partners moved the other way, raising to $725. The consensus mean sits at $671, against a current price of $599, a gap of roughly 12%. Goldman Sachs, which initiated with a Sell rating and a $321 target in late September, remains the clear outlier. The bull case rests on the '327 patent settlement with Liquidia, which removes the worst-case legal scenario for Tyvaso and opens a potential path into IPF with an April 2027 launch. The bear case points to franchise concentration: Tyvaso DPI drives the bulk of revenue, and any loss of PAH market share to Yutrepia above the 33% ceiling embedded in the settlement would put consensus estimates under pressure.

CEO Martine Rothblatt sold roughly 7,580 shares on October 29, valued at approximately $4.5 million in aggregate, under a pre-arranged 10b5-1 plan. Net insider sales over the past 90 days total approximately $29.2 million. Planned sales carry less informational weight than discretionary trades, but the volume is notable alongside the stock's 24% monthly gain. Meanwhile, retail attention has spiked sharply: the ORTEX Wikipedia-view signal registered a z-score of 4.69 against the company's own 90-day history as of October 19, the highest attention reading in the dataset. That kind of retail interest, coinciding with a large short-covering event and a strong monthly price move, is the type of dynamic that can amplify post-earnings moves in either direction.

Wednesday's report will test whether Tyvaso's commercial trajectory in the quarter justifies the price re-rating, and whether management's commentary on the IPF launch timeline and Yutrepia's real-world share impact shifts the debate between the dominant bull and the Goldman-led bear.